REG - Sareum Holdings PLC - Director Dealing

Sareum HoldingsAnnouncement

05/09/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230905:nRSE3434La&default-theme=true

RNS Number : 3434L  Sareum Holdings PLC  05 September 2023

Sareum Holdings PLC

("Sareum" or the "Company")

Director Dealing

Cambridge, UK, 05 September 2023 - Sareum Holdings plc (AIM: SAR), a
clinical-stage biotechnology company developing next generation kinase
inhibitors for autoimmune disease and cancer, announces that Mr Clive Birch,
Non-Executive Director, purchased 4,630 ordinary shares of 0.0125 pence each
in the Company ("Ordinary Shares") at an average price of 82.71 pence per
share on 4 September 2023.

Following the transaction, Mr Clive Birch has a holding in Sareum of 44,597
Ordinary Shares, representing approximately 0.06% of Sareum's current issued
share capital.

The notification below, which has been made in accordance with the
requirements of the Market Abuse Regulation, provides further details.

PDMR Notification Form:

 1           Details of the person discharging managerial responsibilities/person closely
             associated

 a)          Name                            Clive Birch
 2           Reason for the notification
 a)          Position/status                 Non-Executive Director
 b)          Initial notification/amendment  Initial notification
 3           Details of the issuer, emission allowance market participant, auction
             platform, auctioneer or auction monitor
 a)          Name                            Sareum Holdings plc
 b)          LEI                             213800PKERN2DY8FFM72
 4           Details of the transaction(s): section to be repeated for (i) each type of
             instrument; (ii) each type of transaction; (iii) each date; and (iv) each
             place where transactions have been conducted
 a)          Description of the financial instrument, type of instrument     Ordinary shares of 0.0125 pence each in the share capital of Sareum Holdings
                                                                             plc

             Identification code                                             GB00B02RFS12

 b)          Nature of the transaction                                       Purchase of shares
 c)          Price(s) and volume(s)
                                                                                                   Price(s)              Volume(s)
                                                                                                   £0.8322               2,151
                                                                                                   £0.8227               2,479
 d)          Aggregated information

             -      Aggregated volume                                        4,630 ordinary shares

             -      Weighted Average Price                                   82.71 pence per share

 e)          Date of the transaction                                         4 September 2023
 f)          Place of the transaction                                        London Stock Exchange (AIM)

 

The information contained within this announcement is deemed to constitute
inside information as stipulated under the Market Abuse Regulations (EU) No.
596/2014, which is part of UK law by virtue of the European Union (Withdrawal)
Act 2018.

- Ends -

For further information, please contact:

 Sareum Holdings plc

 Tim Mitchell, CEO                                   01223 497700

 Lauren Williams, Head of Investor Relations         ir@sareum.co.uk

 Strand Hanson Limited (Nominated Adviser)

 James Dance / James Bellman                         020 7409 3494

 Peel Hunt LLP (Joint Corporate Broker)

 James Steel / Patrick Birkholm                      020 7418 8900

 Hybridan LLP (Joint Corporate Broker)

 Claire Noyce                                        020 3764 2341

 Consilium Strategic Communications (Financial PR)

 Jessica Hodgson / Davide Salvi / Stella Lempidaki   020 3709 5700

 

About Sareum

Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing
next generation kinase inhibitors for autoimmune disease and cancer.

The Company is focused on developing next generation small molecules which
modify the activity of the JAK kinase family and have best-in-class potential.
Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801
is a potential treatment for a range of autoimmune diseases and has entered
Phase 1a/b clinical development with an initial focus on psoriasis.

Sareum has an economic interest in SRA737, a clinical-stage Chk1 inhibitor
which it originally developed in collaboration with several Cancer Research
UK-related organisations. SRA737 has shown promising safety and efficacy in
two Phase 1/2 clinical trials.

Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential
application for cancer immunotherapy.

Sareum Holdings plc is based in Cambridge, UK, and is listed on the AIM market
of the London Stock Exchange, trading under the ticker SAR. For further
information, please visit the Company's website at www.sareum.com
(about:blank)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHBZLLBXKLXBBZ